A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: Rapid onset of effect

CNS Drugs

Volumn 22, Issue 8, 2008, Pages 693-704

  Brams, Matthew ^a   Muniz, Rafael ^b   Childress, Ann ^c   Giblin, John ^d   Mao, Alice ^a   Turnbow, John ^e   Borrello, Mary ^b   McCague, Kevin ^b   Lopez, Frank A ^f   Silva, Raul ^g  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Center for Psychiatry and Behavioral Medicine   (United States)

^d Clinical Study Centers LLC   (United States)

^e Westex Clinical Investigations   (United States)

^f Children's Developmental Center   (United States)

^g NEW YORK UNIVERSITY CHILD STUDY CENTER   (United States)

Author keywords

Attention deficit hyperactivity disorder, treatment; Central nervous system stimulants, therapeutic use; Dexmethylphenidate, therapeutic use

Indexed keywords

DEXMETHYLPHENIDATE; METHYLPHENIDATE; PLACEBO;

ABDOMINAL PAIN; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; CONNERS ADHD/DSM IV SCALE FOR PARENTS; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HUMAN; INCREASED APPETITE; MAJOR CLINICAL STUDY; MALE; MATH TEST ATTEMPTED SCORE; MATH TEST CORRECT SCORE; MULTICENTER STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHOOL CHILD; SKAMP ATTENTION SCORE; SKAMP DEPORTMENT SCORE; SKAMP RATING SCALE; VIRAL GASTROENTERITIS; VITAL SIGN;

ANALYSIS OF VARIANCE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; DRUG EVALUATION; FEMALE; HUMANS; MALE; METHYLPHENIDATE; PERSONALITY ASSESSMENT; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 46749156887     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200822080-00006     Document Type: Article

References (32)

1. Goldman LS, Genel M, Bezman RJ, et al. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. JAMA 1998; 279: 1100-7
2. Biederman J, Faraone SC. Attention-deficit hyperactivity disorder. Lancet 2005; 367: 237-48
3. Sawyer MG, Whaites L, Rey JM, et al. Health-related quality of life of children and adolescents with mental disorders. J Am Acad Child Adolesc Psychiatry 2002; 41: 530-7
4. DeVeaugh-Geiss J, Conners CK, Sarkis EH, et al. GW320659 for the treatment of attention-deficit/hyperactivity disorder in children. J Am Acad Child Adolesc Psychiatry 2002; 41: 914-20
5. Bastiaansen D, Koot HM, Ferdinand RF, et al. Quality of life in children with psychiatric disorders: self, parent, and clinician report. J Am Acad Child Adolesc Psychiatry 2004; 43: 221-30
6. Klassen A, Miller A, Fine S. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. Pediatrics 2004; 114: E541-7
7. Quinn D, Wigal S, Swanson J, et al. Comparative pharmaco-dynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2004; 43: 1422-9
8. Wigal S, Swanson JM, Feifel D, et al. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2004; 43: 1406-14
9. Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta methylphenidate versus three-times-daily methyl-phenidate in laboratory and natural settings. Pediatrics 2001; 107: E105
10. Swanson JM, Wigal SB, Wigal T, et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (COMACS Study). Pediatrics 2004; 113: E206-16
11. Lopez F, Silva R, Pestreich L, et al. Comparative efficacy of two once-daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day. Pediatr Drugs 2003; 5: 545-55
12. Silva R, Muniz R, Pestreich LK, et al. Efficacy of two long-acting methylphenidate formulations in children with attention-deficit/hyperactivity disorder in a laboratory classroom setting. J Child Adolesc Psychopharmacol 2005; 15: 637-54
13. Swanson J. Compliance with stimulants for attention-deficit/ hyperactivity disorder: issues and approaches for improvement. CNS Drugs 2003; 17: 117-31
14. Wilens TE, Gignac M, Swezey A, et al. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry 2006; 45: 408-14
15. Lage M, Hwang P. Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment. J Child Adolesc Psychopharmacol 2004; 4 (4): 575-81
16. Thiruchelvam D, Charach A, Schachar RJ. Moderators and mediators of long-term adherence to stimulant treatment in children with ADHD. J Am Acad Child Adolesc Psychiatry 2001; 40 (8): 922-8
17. Living with ADHD: a survey among US parents of children/ teenagers and adult sufferers. Conducted by Harris Interactive for Feinstein Kean Healthcare, 2007 Mar 27 [online]. Available from URL: http://www.harrisinteractive.com/ harris_poll/ [Accessed 2008 Mar 31]
18. Srinivas NR, Hubbard JW, Quinn D, et al. Enantioselective pharmacokinetics and pharmacodynamics of dl-threo-methyl-phenidate in children with attention deficit hyperactivity disorder. Clin Pharmacol Ther 1992; 52: 561-8
19. Markowitz JS, DeVane CL, Pestreich LK, et al. Comprehensive in vitro screening of d-, l- and dl-threo-methylphenidate: an exploratory study. J Child Adolesc Psychopharmacol 2006; 16: 687-98
20. Novartis Pharmaceuticals. Focalin® XR: prescribing information [online]. Available from URL: http://www.pharma.us.novartis.com/product/pi/pdf/ focalinXR.pdf [Accessed 2008 Mar 20]
21. Silva RR, Munix R, Pestreich L, et al. Dexmethylphenidate extended release capsules in children with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2008; 47: 199-208
22. Silva RR, Muniz R, McCague K, et al. Treatment of children with attention-deficit/hyperactivity disorder (ADHD): results of a randomized, multicenter, double-blind, crossover study of extended-release dexmethylphenidate and d,l-methylphenidate and placebo in a laboratory classroom setting. Psychopharmacol Bulletin 2008; 41: 19-33
23. Muniz R, Brams M, Mao A, et al. Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention deficit hyperactivity disorder: a 12-hour laboratory classroom study. J Child Adolesc Psychopharmacol 2008; 18: 248-56
24. Swanson JM, Kinsbourne M, Roberts W, et al. A time-response analysis of effect of stimulant medication on the learning ability of children referred for hyperactivity. Pediatrics 1978; 61: 21-9
25. Swanson JM, Wigal S, Greenhill L, et al. Analog classroom assessment of Adderall in children with ADHD. J Am Acad Child Adolesc Psychiatry 1998; 37: 519-26
26. Wigal S, Gupta S, Guinta D, et al. Reliability of the SKAMP Rating Scale in a laboratory school setting. Psychopharmacol Bull 1998; 34: 47-53
27. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994: 78-85
28. Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997; 36: 980-8
29. Swanson JM, Wigal S, Greenhill L, et al. Subjective and objective measures of the pharmacodynamic effects of Adderall in the treatment of children with ADHD in a controlled laboratory classroom setting. Psychopharmacol Bull 1998; 34: 55-61
30. Swanson JM, Wigal SB, Udrea D, et al. Evaluation of individual subjects in the analog classroom setting: I. Examples of graphical and statistical procedures for within-subject ranking of responses to different delivery patterns of methylphenidate. Psychopharmacol Bull 1998; 34: 825-32
31. Conners CK, Parker JD, Sitarenios G, et al. The revised Conners' Parent Rating Scale: factor, structure, reliability, and criterion validity. J Abnormal Child Psychology 1998; 26: 257-68
32. Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention deficit/hyperacitvity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 2004; 114: E1-8